Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ProQR Therapeutics N.V. - Ordinary Shares
(NQ:
PRQR
)
1.519
+0.069 (+4.76%)
Streaming Delayed Price
Updated: 10:30 AM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ProQR Therapeutics N.V. - Ordinary Shares
< Previous
1
2
Next >
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 15, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 22, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Lilly and ProQR to Expand RNA Editing Collaboration
December 22, 2022
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
November 14, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 09, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
November 03, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today